|
What is Tetrasil?
Tetrasil® is a powerful multi-purpose topical ointment.
Customers worldwide have used it for the treatment of a wide
range of skin conditions. Tetrasil's key ingredient, Tetrasilver Tetroxide
(TST™), has a natural attraction to the
surface of bacteria, fungi and viruses. These pathogens are
responsible for the itching, rashes, redness, burning and other
unwanted symptoms of the skin conditions. Upon contact, TST's unique chemical structure releases both a micro
electrical charge and oxygen, which immediately begins to kill
the pathogens. Customers say the result is not just rapid
relief, but elimination of the root cause. Tetrasil® is protected
by US and international patents, with additional patents
pending.
Chemistry
Tetrasil® contains Tetrasilver Tetroxide (TST™), suspended in an
ointment base (organic wax, Jojoba oil). TST™ is a small inorganic,
semi-conducting molecular crystal that contains two monovalent and
two trivalent silver ions that are electrically balanced by four
oxygen ions. The chemical formula for TST™ is Ag4O4. Unlike
colloidal silver, which is just a single silver ion, TST™ is a
multi-valent molecule with a naturally occurring electrical
potential many times more powerful than colloidal silver. Further,
unlike colloidal silver, TST™ does not bind with healthy tissue.
Mechanism of Action
Theoretical depiction at microbial level:

1. ATTRACTION
Illustrated above is a virus (large
ball formation) in the early stages of attack by an array of TST™ molecules (small blue particles).
Within minutes of application, millions of TST™ molecules are
strongly attracted to and react with the
harmful microorganisms. |

2. CONTACT & ELECTRICAL SHOCK
Upon contact of each TST™ molecule with the pathogen’s surface
chemicals, the TST™ molecule releases a micro electrical charge.
This electrical shock, it is theorized, destroys the ability of
the pathogen’s ability to process information and survive. |

3. CHEMICAL BINDING, OXYGEN
RELEASE & MICROBIAL DEATH
The TST™ molecules then bond,
chemically, with the pathogen, in a process known as a “redox”
reaction. As a result, the microbe dies from the metallic bonding
and electrical bombardment. Furthermore, oxygen is released,
providing additional benefits for healthy cells nearby.
|
In-vitro Laboratory Testing
An
extensive battery of testing on TST™ with renown Contract Research
Organizations (CROs) has been performed. The results are quite compelling results. See links
below:
EPA Safety Data on TST™
The US Environmental Protection Agency (EPA)
directed a study of TST™ and awarded it a Category 4 designation
(their highest safety rating) as a powerful anti-microbial (for use
in swimming pools and spas) after a battery of oral, dermal and
ocular toxicity tests. See EPA Registration No. 3432-64. Trials were
conducted between the EPA and Antelman Technologies, then licensed
to a third-party company for manufacturing and marketing rights.
Note: The US Food & Drug Administration (FDA) has not yet reviewed
or approved TST™ for therapeutic use.
Manufacturing and Handling
Procedures and quality controls have been developed and established
to ensure that the supply and proper handling of Tetrasil® is
consistently manufactured to strict standards, following US Food &
Drug Administration Good Manufacturing Procedure (GMP) guidelines in
GMP-registered facilities.
In-vitro Laboratory Testing Table
The following table presents the Minimum Inhibitory
Concentration (MIC), in parts per million, of TST required to destroy
the pathogens shown. Source: Aidance Skincare & Topical
Solutions, LLC. All tests were stated to have been "performed
by recognized contract research organizations at FDA-certified
laboratories."
| |
Microorganism
|
Minimum Lethal Concentration
Parts-Per-Million
|
|
Gram Negative Bacteria |
| |
Escherichia coli 10231
|
2.50 |
| |
Escherichia coli 25254
|
2.50 |
| |
Enterobacter cloacae 13047
|
2.50 |
| |
Pseudomonas aeruginosa 9027
|
1.25-2.50 |
| |
Salmonella |
< 2 |
|
Gram Positive Bacteria |
| |
Bacillus Anthracis
(Anthrax) |
< 70.00 |
| |
Bacillus subtilis 6633
|
5.00 |
| |
Micrococcus lutena 9341
|
1.25-2.50 |
| |
Staphylococcus aureus 0927
|
2.50-5.00 |
| |
Staphylococcus aureus 27543
|
5.00 |
| |
Staphylococcus epidermidis
12228 |
0.625 |
| |
Streptococcus agalactiae
27956 |
1.25-5.00 |
| |
Streptococcus faecium 10541
|
5.00 |
| |
Streptococcus pyogenes 7958
|
2.50 |
| |
Streptococcus faecalis |
0.50 |
|
Antibiotic–Resistant* and Susceptible Bacteria |
| |
E. coli |
32.00 |
| |
S. aureus |
32.00 |
| |
K. pneumoniae |
16.00 |
| |
S. agalactiae (Group B) |
32.00 |
| |
P. aeruginosa |
16.00 |
| |
S. pyogenes |
16.00 |
| |
E. faecalis ATCC 29212 * |
32.00 |
| |
E. faecium ATCC 700221 * |
16.00 |
| |
* Vancomycin-resistant
|
|
|
Yeast and Mold |
| |
Candida albicans 16404 |
2.50-5.00 |
| |
Saccharomyces cerevisiae 2601 |
1.25 |
|
Viruses |
| |
Herpes Simplex- HSV-1, HSV-2 |
< 96.00 |
|